Find and Pitch Jounalists, Get Your Story Covered

Tags: DLBCL Diffuse Large B Cell Lymphoma Bispecific Antibodies DLBCL Trials toxicity management

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Scottish medicines consortium approves CAR T-cell therapy for blood cancer - 4 days ago
2	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FLASCO Fall Session: Advancements in MRD Monitoring Using ctDNA in Lung Cancer - 12 days ago Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 2 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - 10 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - 11 months ago
3	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances With Various Therapies Targeting DLL3 in Lung Neuroendocrine Tumors - 2 months ago GSK5764227 Receives Breakthrough Therapy Designation to Treat Extensive-Stage Small–Cell Lung Cancer - 3 months ago FDA Grants Priority Review for Durvalumab to Treat Small Cell Lung Cancer - 3 months ago Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer - 7 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 8 months ago Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC - 8 months ago Phase 3 EVOKE-01 Study in Metastatic NSCLC Falls Short of Primary Endpoint - 9 months ago
4	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Trial Questions Role of Dual Immunotherapy in First-Line NSCLC - 3 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 8 months ago Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results - 9 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - 9 months ago Can ctDNA Guide Radiation Use in Oligometastatic NSCLC? - about 1 year ago
5	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	'Very Clear Signal' That Survival Improved With Addition of Durvalumab in SCLC - 4 months ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 4 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 5 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 10 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - 10 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 11 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Positive Results for Odronextamab in Relapsed/Refractory DLBCL - 11 months ago The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer - about 1 year ago
6	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Brentuximab Vedotin Shows 37% Reduction in Risk of Death for DLBCL - 5 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 8 months ago Samsung Bioepis Initiates Phase 1 Trial for Proposed Keytruda Biosimilar - 9 months ago
7	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 5 months ago FDA Approves First CAR-T for Chronic Lymphocytic Leukemia - 8 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 11 months ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - 11 months ago Non-Covalent BTK Inhibitor Approved for CLL - 12 months ago
8	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 9 months ago
9	Erin Hunter, Assistant Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	More than 80% of Patients with Diffuse Large B-cell Lymphoma Responded to Novel Therapeutic, according to the Results of a Preclinical Trial - 11 months ago FDA Updates Label for Axicabtagene Ciloleucel for R/R LBCL Following Positive Long-Term Survival Data - 11 months ago Hispanic Patients with Philadelphia (Ph)-Like B-cell Acute Lymphoblastic Leukemia Continue to Experience Poor Outcomes, According to Expert - 11 months ago Drug Sequence Might Not Significantly Impact Survival Outcomes of Patients with Lymphoma - 11 months ago Golidocitinib Demonstrates Significant Survival Benefits For Patients with Peripheral T-cell Lymphoma - 11 months ago Phase 3 Trial Shows Neoadjuvant, Adjuvant Nivolumab Can Improve Survival in Patients With Lung Cancer - about 1 year ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	FDA Approves Lilly's Jaypirca for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma - 12 months ago FDA Grants Priority Review to Expand Indication for Bristol Myers Squibb’s Breyanzi in CLL, SLL - about 1 year ago

Journalists covering DLBCL Trials